RESEARCH

Single-cell RNA sequencing reveals markers of disease progression in primary cutaneous T-cell lymphoma

Katharina Rindler¹, Constanze Jonak¹, Natalia Alkon¹, Felix M. Thaler¹, Harald Kurz¹, Lisa E. Shaw¹, Georg Stingl¹, Wolfgang Weninger¹, Florian Halbritter², Wolfgang M. Bauer¹, Matthias Farlik¹† and Patrick M. Brunner¹*†

Abstract

Background: In early-stage mycosis fungoides (MF), the most common primary cutaneous T-cell lymphoma, limited skin involvement with patches and plaques is associated with a favorable prognosis. Nevertheless, approximately 20–30% of cases progress to tumors or erythroderma, resulting in poor outcome. At present, factors contributing to this switch from indolent to aggressive disease are only insufficiently understood.

Methods: In patients with advanced-stage MF, we compared patches with longstanding history to newly developed plaques and tumors by using single-cell RNA sequencing, and compared results with early-stage MF as well as nonlesional MF and healthy control skin.

Results: Despite considerable inter-individual variability, lesion progression was uniformly associated with downregulation of the tissue residency markers \(\text{CXCR4}\) and \(\text{CD69}\), the heat shock protein \(\text{HSPA1A}\), the tumor suppressors and immunoregulatory mediators \(\text{ZFP36}\) and \(\text{TXNIP}\), and the interleukin 7 receptor (\(\text{IL7R}\)) within the malignant clone, but not in benign T cells. This phenomenon was not only found in conventional TCR-αβ MF, but also in a case of TCR-γδ MF, suggesting a common mechanism across MF subtypes. Conversely, malignant cells in clinically unaffected skin from MF patients showed upregulation of these markers.

Conclusions: Our data reveal a specific panel of biomarkers that might be used for monitoring MF disease progression. Altered expression of these genes may underlie the switch in clinical phenotype observed in advanced-stage MF.

Keywords: Cutaneous lymphoma, Mycosis fungoides, Single-cell RNA sequencing, Gamma-delta lymphoma, Advanced-stage MF, Early-stage MF, Nonlesional MF

Introduction

Primary cutaneous T-cell lymphomas (CTCL) comprise a clinically and biologically heterogeneous group of malignancies arising from the clonal proliferation of skin-homing or skin-resident T cells [1]. The most frequent clinical entity is mycosis fungoides (MF), accounting for approximately 60% of all cases [2, 3]. In early disease stage, MF presents with patches and/or plaques, which often remain stable over many years without phenotypic changes or metastatic spread [4]. However, in approximately 20–30% of cases, MF progresses to advanced-stage disease by developing skin tumors and/or erythroderma, and ultimately disseminates to blood, lymph nodes and internal organs. This results in an unfavorable 5-year overall survival of less than 40% [5–8]. In the skin, the transition from early indolent to progressive disease is accompanied by a shift from a more...
type-1- towards a type-2-dominant immune signature of the tumor micromilieu [9], potential loss of certain T-cell antigens (CD2, CD3, CD5, CD7) [10] and/or loss of epidermotropism [11], but exact cell-intrinsic mechanisms and modes of intercellular communication driving this progression are still only insufficiently understood. Importantly, there are currently no molecular biomarkers available that can reliably predict disease outcome [12].

Thus, a better understanding of factors driving cancer cell progression is urgently needed. However, disease heterogeneity of MF, both on clinical and molecular levels, is a major challenge in this regard [12–15]. In this study, we profiled patches with longstanding history, and compared them with recently developed plaques or tumors within the same patient to overcome inter-individual variability. Follow-up skin biopsies were taken upon changes in phenotype or after therapeutic response. In addition, results were compared with early-stage disease, clinically unaffected (nonlesional) MF skin as well as control skin from healthy individuals. By using single-cell RNA sequencing (scRNA-seq) combined with T-cell receptor (TCR) sequencing, our data reveal a characteristic panel of six markers to be consistently downregulated in clonally expanded T cells of advancing MF lesions, as opposed to patches from indolent early-stage disease or clinically unaffected skin. Given the involvement of these markers in tissue retention, tumor suppression and inflammatory responses, they might be directly involved in mechanisms driving MF progression.

Patients and methods
Patient recruitment and sample processing
The study was conducted under a protocol approved by the Ethics Committee of the Medical University of Vienna, Austria (EK 1360/2018). Patients were recruited via our skin lymphoma clinic. Patient details are shown in Table 1. Punch biopsies were taken from clinically affected (lesional) and clinically unaffected (nonlesional) skin of MF patients, as well as healthy control individuals after obtaining written informed consent. For each described sample, one single 6 mm punch biopsy was taken and processed immediately. Each sample was cut into small pieces and digested in the C Tube (Miltenyi Biotec, Bergisch Gladbach, Germany) using the enzyme mix as provided by the Whole Skin Dissociation Kit for human (Miltenyi Biotec) in a total volume of 0.5 ml RPMI medium with enzymatic supplements as described in the manufacturer’s instructions. The sample was then incubated for a total of 1 hour in a water bath at 37°C. The sample was then further dissociated using the gentleMACS Dissociator (Miltenyi Biotec) running the program h_skin_01. After termination of the program steps 10–14 were conducted as detailed in the manufacturer's instructions. Finally, the cell pellet was resuspended in PBS with 0.08% BSA reaching a total volume of not more than 100 μl. A cell aliquot was stained with trypan blue and cell numbers and percentages of dead cells were assessed by manual counting. Samples with not more than 30% dead cells were then subjected to scRNA-seq processing as detailed below.

Droplet-based single cell RNA sequencing
Single cell suspensions were subjected to scRNA-seq using the Chromium Single Cell Controller and Single Cell 5’ Library & Gel Bead Kit v1.1 (10X Genomics, Pleasanton, CA), according to the manufacturer's protocol. A total of 25,000 cells were loaded for each sample on the Chip G (10X Genomics). cDNA was amplified using 13 PCR cycles. DNA concentration was assessed using the Qubit 1X dsDNA HS Assay Kit (Thermo Fisher Scientific) and fragment distribution was determined using the D5000 Screen Tape and the Tape Station 4150 system (Agilent Technologies, Santa Clara, CA). TCR αβ sequences were enriched from the cDNA using the respective reagents, and following the instructions of the VDJ Kit workflow by 10X Genomics with no adjustments. γδ TCR amplification from cDNA was performed by adhering to the primers and protocol procedure depicted in the ECCITE-seq workflow by Mimitou et al. [16]. Library preparation and enrichment was conducted following the manufacturer’s instructions (10X Genomics) and final quality control was carried out using the Qubit 1X dsDNA HS Assay Kit (Thermo Fisher Scientific) and the D1000 Screen Tape and the Tape Station 4150 system (Agilent Technologies). Sequencing was performed using the Illumina NovaSeq 6000 instrument and the SP platform in the 150bp paired-end configuration.

For detailed methods on single-cell RNAseq data analysis, as well as immunofluorescence microscopy and quantitative RT-PCR procedures, please see supplemental methods.

Results
Single-cell RNA-seq mapping mycosis fungoides skin lesions
We investigated three adult CTCL patients (MF309, MF311 and MF312, Table 1) suffering from advanced-stage MF (stage IIb or higher), previously confirmed by conventional histopathology (Fig. 1 A). Two patients (MF309, MF312) met histopathological criteria for large-cell transformation (Table 1), a feature associated with an unfavorable disease course [5]. At time of study inclusion, each patient showed both flat, stable patches of >6 months duration, as well as recently developing palpable plaques and/or tumors. From each patient, we took biopsies from both a flat and a palpable lesion at the same
Table 1 Patient baseline characteristics at time of sampling

| Subject ID | scRNA-seq | FACS/RT-PCR Samples biopsied for scRNA-seq | Age | Sex | Ethnicity | Diagnosis | Large cell transformation | Disease duration (years) | Ongoing treatment | Previous treatments | Disease stage |
|------------|-----------|--------------------------------------------|-----|-----|-----------|-----------|---------------------------|-------------------------|------------------|-------------------|--------------|
| MF309      | x         | Patch and tumor (trunk)                    | 76  | Male| Caucasian | CD4+ MF, CD30+ | Present                   | Diagnosis 22 years ago; symptoms reported since age 37 | ECP              | Topical GCS, IFN alpha | IA1 (T3N0M0B2) |
| MF309      | x         | Ulcerated tumor (follow-up lesion trunk) and nonlesional skin (trunk) | 76  | Male| Caucasian | CD4+ MF, CD30+ | Present                   | ECP              | Brentuximab | MA1 (T3N0M0B2)    |
| MF311      | x         | Patch and plaque (trunk)                   | 74  | Female| Caucasian | CD4+ MF, CD30- | Absent                   | Diagnosis 2 years ago; symptoms reported since age 53 | ECP              | NB-UVB, bexarotene, PUVA, topical and systemic GCS, IFN alpha, alemtuzumab, local radiotherapy (x ray) | IVA1 (T2N1M0B2) |
| MF311      | x         | Nonlesional skin (lower extremity)         | 74  | Male| Caucasian | CD4+ MF, CD30- | Absent                   | ECP              | MA1 (T2N1M0B2)    |
| MF311      | x         | Erythroderma (follow-up lesion upper extremity) | 75  | Male| Caucasian | CD4+ MF, CD30- | Absent                   | ECP, chlorambucil, systemic GCS | MA1 (T4N1M0B2)    |
| MF312      | x         | Patch and plaque (upper extremity)         | 55  | Male| Caucasian | CD4+ MF, CD30+ | Present                   | Diagnosis 6 years ago; symptoms since age 44 | ECP, IFN alpha, actretin | Topical GCS, NB-UVB, local radiotherapy (x ray) | IIB* (T2bN0M0B0) |
| MF312      | x         | Cleared (follow-up lesion (upper extremity) | 56  | n.a. |           |            | n.a.                     | ECP, chlorothalidine | IIB* (T1aN0M0B0) |
| MF318      | x         | Patch and plaque (thigh)                   | 55  | Female| Caucasian | gamma/delta MF, CD30+ | Absent                   | Symptoms since age 52; recently diagnosed | none             | Topical GCS and CNI, NB-UVB | IIB** (T3N0M0B0) |
| P65        | x         | Patch and non-lesional skin (upper extremity) | 53  | Male| Caucasian | CD4+ MF, CD30- | Absent                   | Symptoms for > 10 years, recently diagnosed | none             | Topical GCS | IB (T2aN0M0B0)    |
| P107       | x         | Patch lower back                           | 39  | Female| Caucasian | CD4-/CD8-MF, CD30+ | Absent                   | Symptoms for > 20 years, diagnosed at age 37 | none             | Topical GCS | IA (T1bN0M0B0)    |
Table 1 (continued)

| Subject ID | scRNA-seq | FACS/RT-PCR Samples biopsied for scRNA-seq | Age | Sex | Ethnicity | Diagnosis | Large cell transformation | Disease duration (years) | Ongoing treatment | Previous treatments | Disease stage |
|------------|-----------|--------------------------------------------|-----|-----|-----------|-----------|--------------------------|------------------------|-------------------|------------------|--------------|
| P107       | x         | Plaque lower back                           | 39  | Female | Caucasian | CD4−/CD8-MF, CD30+ | Absent                  | Symptoms for >20 years; diagnosed at age 37 | none             | Topical GCS     | IA (T1bN0M0B0) |
| P138       | x         | Patch thigh                                 | 47  | Male  | Caucasian | CD4 + MF    | Absent                  | Symptoms for >20 years; recently diagnosed | none             | Topical GCS     | IA (T1aN0M0B0) |
| P73        | x         | Plaque and non-lesional skin (lower extremity) | 82  | Male  | Caucasian | folliculotropic MF, CD30- | Absent                  | Diagnosis 6 years ago | none             | PUVA, topical GCS, Re-PUVA, local radiotherapy | IIB (T3N0M0B0) |
| P84        | x         | Plaque (upper extremity)                    | 75  | Male  | Caucasian | CD4 + MF, CD30- | Absent                  | Symptoms for 6 months; recently diagnosed | none             | NB-UVB, topical GCS | IIB (T3N0M0B1) |
| P84        | x         | Cleared (follow-up) lesion (upper extremity) | 75  |       |           | CD4+ MF, CD30- | Absent                  |                        | PUVA             |                  | IIB (T3N0M0B1) |
| P90        | x         | Patch and non-lesional skin (upper extremity) | 75  | Male  | Caucasian | CD4 + MF    | Absent                  | Diagnosis at age 64 | none             | topical GCS, PUVA, NB-UVB, bexarotene, acitretin | IB (T2aN0M0B0) |
| P15        | x         | Tumor trunk                                 | 59  | Male  | Caucasian | CD4 + MF, CD30+ | Present                | Diagnosis at age 56 | Brentuximab vedotin | Topical and systemic GCS | IIB (T3N0M0B0) |
| P182       | x         | Patch and plaque (trunk)                    | 49  | Female | Caucasian | CD4 + CD8 + MF, CD30+ | Absent                 | Onset of symptoms 4 months ago; recently diagnosed | none             |                  | IA (T1bN0M0B1) |
| P112       | x         | Healthy control skin                        | 51  | Female | Caucasian | n.a.         | n.a.                   | n.a.                  | none             | n.a.             | n.a.          |
| P115       | x         | Healthy control skin                        | 48  | Male  | Caucasian | n.a.         | n.a.                   | n.a.                  | none             | n.a.             | n.a.          |
| P116       | x         | Healthy control skin                        | 57  | Female | Caucasian | n.a.         | n.a.                   | n.a.                  | none             | n.a.             | n.a.          |
| P121       | x         | Healthy control skin                        | 44  | Female | Caucasian | n.a.         | n.a.                   | n.a.                  | none             | n.a.             | n.a.          |

ECP Extracorporeal photopheresis, GCS glucocorticosteroids, IFN interferon, PUVA psoralen ultraviolet A photochemotherapy, NB-UVB narrow band ultraviolet B phototherapy, CNI calcineurin inhibitor, MF mycosis fungoides; *history of skin tumors successfully treated with local radiotherapy, **tumor was not biopsied, only patch and plaque
time and from the same body region as adjacent as possible (Fig. 1 B), and performed single-cell RNA sequencing (scRNA-seq). Data were analyzed using the Seurat toolkit in R [17, 18]. After integration, we obtained a total of 47,172 cells, comprising 17,471 from three patches and 29,701 from three plaque/tumor lesions (Table S1). Data visualization using uniform manifold approximation and projection for dimension reduction (UMAP) [19] followed by unsupervised clustering depicted 28 distinct clusters (Fig. 1 C, S1A-B). We attributed cell identities using canonical markers and top upregulated genes (according to the smallest adjusted p-value and average log fold change) for each cluster compared to the rest of the dataset (Fig. S1C-D, Table S2). The largest cluster comprised CD3D+ T cells, consisting of mutually exclusive populations of CD8A+ GZMA+ cytotoxic (TC-5) and CD4+ T-helper cells (TC-2: CCR7; TC-3: CXCL13; TC-4: TNCRSF4; TC-6: CCR4; TC-9: CCR7, MX1), including FOXP3+ CTLA4+ regulatory T cells (TC-1) and proliferating T cells (TC-7) (Fig. S1C, Table S2). By contrast, one CD3D+ cluster (TC-8) seemed largely negative for both CD4 and CD8A that was mainly derived from patient MF309 (Fig. S1C, Table S1). Re-examination of histopathological slides of this patient indeed suggested some MF cells to be negative for CD4 (data not shown). While type 1 (IFNG) and type 17/22 (IL17A, IL22, IL26) cytokines were mostly found in clusters TC-5/TC-8 and TC-8, respectively, the type-2 cytokine IL13 was found at low frequencies across several clusters (Fig. S1E). A myeloid cell cluster contained dendritic cells (DC-1: CD1A, CD1C, and partly CD207; DC-2: LYZ, IL1B; DC-3: LAMP2) and macrophages (MPh1: CD163, CCL18; MPh2: CPVL). Smaller leukocyte clusters included B cells (CD19), plasmacytoid DCs (pDCs: LILRA4) and plasma cells (PC: IGKC). A larger population of COL1A2+ fibroblasts contained five clusters (FB-1: COL1A1, MFAP5, FBN1-positive cells constituting the largest group [20]; FB-2: CCL19, CXCL9; FB-3: POSTN, CCL2, COL6A5, COL18A1 and CCL19 cells previously described as inflammatory fibroblasts in AD [21]; FB-4: APOD, CFD, APOE, CXCL12; and FB-5: COL1A1, SPARC; Fig. 1 C, Fig. S1C-D, Table S2). We also found KRT5+ keratinocytes (basal KC-1: KRT15, KRT14; suprabasal KC-2: KRT1, KRT10, Fig. S1D), myofibroblasts (MF8: ACTA2), blood endothelial cells EC-1 and EC-2 (VWF) and lymphoendothelial cells (LEC: LYVE1, PDPN) (Fig. S1C-D). These data demonstrate the presence of all major skin cell types and clusters in each individual sample, except for TC-9, which was found primarily in MF311 patch lesions (Fig. 1 D, Table S1, Fig. S2A-F).

**T-cell receptor (TCR) sequencing detects considerable inter-individual transcriptomic heterogeneity in the dominant T cell clone**

Both in patch and plaque/tumor lesions, T cells represented the largest fraction of cells (Fig. 1 C, Table S1). Most of the nine individual T-cell clusters were found in all three patients, except for TC-9, that was mainly present in MF311 (Fig. 2 A), characterized by the overexpression of the chemokine receptor CCR7 (Table S2) that is typically found in recirculating T cells [22]. By combining 5’ scRNA-seq with αβ T-cell receptor (TCR) sequencing, we defined the top expanded clone within each patient (Fig. 2 B). This clone comprised 58.4, 84.0 and 47.6% of all TCR-positive cells in MF309, MF311 and MF312, respectively, (Fig. S2G-H), thus most likely constituting the malignant clone [23]. Clonally expanded cells were primarily found in CD4+ clusters TC-2, TC-3, TC-4, TC-6, TC-7, TC-8 and TC-9, while TC-1 (helper and regulatory T cells) and TC-5 (cytotoxic T cells) largely consisted of polyclonal T cells (Fig. 2 C-D). To better understand transcriptomic features of putatively malignant (monoclonal) vs. benign (polyclonal) T cells, we calculated differentially expressed genes (DEGs) between these two groups and displayed top DEGs in a heat map (Fig. 2 E). We found considerable inter-patient variability in monoclonal populations, while gene expression in polyclonal cells seemed more homogeneous (Fig. 2 E, Fig. S2I), despite the fact that the latter comprised both CD4+ and CD8A+ subsets. Patient-to-patient heterogeneity was also clearly visible when DEGs in monoclonal vs. polyclonal T cells were calculated for each patient separately (Fig. S2J-L). One of the few markers generally downregulated in malignant cells included CD7 (Fig. 2 F, S2J-L), in line with a malignant phenotype, and as seen in histopathology (Fig. 1 A) [24]. Other genes largely absent in monoclonal cells included the prototypic type 1 cytokine INFγ, the cytotoxic molecules GZMA and GZMK, and the chemokine ligand CCL4 (Fig. 2 E), which were mostly found in benign CD8A+ cells (Fig. 2 G-I), in line with cytotoxic T cells. Similarly, lymphoma cells lacked CTLA4 expression (Fig. 2 E), which was mostly present in
**Fig. 1** (See legend on previous page.)
markers were also downregulated in benign T cell populations, harboring a malignant phenotype. Notably, the dominant clones showed considerable inter-individual transcriptomic heterogeneity.

\( \text{CXCR4, CD69, HSPA1A, ZFP36, IL7R and TXNIP are consis-}
\text{tently downregulated in the malignant clone in palpable vs. flat skin lesions} \)

To investigate markers of skin lesion progression, we compared patch vs. plaque or tumor lesions for each patient individually, by calculating total numbers of DEGs per cluster (Fig. 3 A-C). Within T cells, three malignant clusters displayed the highest numbers of DEGs (TC-8 in MF309, TC-4 in MF311, and TC-3 in MF312), while benign clusters TC-1 and TC-5 harbored only a few DEGs. When comparing malignant clones in plaque/tumor vs. patch lesions (Fig. 3 D-F, Table S3), we did not find DEGs that were consistently upregulated in all three patients (Fig. 3 G). By contrast, we discovered six genes to be downregulated in all patients in plaque/tumor vs. patch lesions, namely the chemokine receptor CXCR4, the skin residency marker CD69, the heat shock protein HSPA1A, the anti-inflammatory mediator tristetraprolin (i.e. zinc finger protein 36 homolog ZFP36), the interleukin-7 receptor IL7R, and the thioredoxin-interacting protein TXNIP (Fig. 3 H, Table S3). While some of these markers were also downregulated in benign T cell populations including CD4+ helper T cells, CD8A+ cytotoxic T cells, and FOXP3+ regulatory T cells, consistent downregulation across all three patients was only observed in malignant cells (Fig. 3 I, Table S3). Importantly, no single other gene was consistently regulated in benign T cell populations between plaque/tumor and patch lesions in all three patients (Table S3). By using immunohistochemistry, we were able to confirm that malignant cells (as defined by staining of the expanded clone with antibodies specific for the respective T-cell receptor beta chain) co-expressed the cell surface markers CD69, CXCR4, and IL7R (CD127) on a protein level (Fig. 3 J). We also assessed marker expression of lymphoma cells isolated from three patch and five plaque/tumor MF skin lesions by flow cytometry-based cell sorting (Fig. S3A-B), confirming similar decreases in all markers except for TXNIP. These data suggest that CXCR4, CD69, HSPA1A, ZFP36, IL7R (and possibly TXNIP) represent potential markers of disease progression that are common to the malignant clone in the three MF patients investigated.

Cells of the lymphoma microenvironment only show few consistent transcriptomic changes from patch to plaque/tumor lesions

Besides the malignant clone, benign infiltrating immune cells as well as non-leukocytes are assumed to be involved in the advancement of cutaneous lymphoma lesions [9]. However, DEGs between plaque/tumor vs. patch lesions were generally low in non-malignant cells (Fig. 4 A, Table S4), with single patients dominating the transcriptomic pattern of certain cell clusters (Fig. 3 A-C). When comparing DEGs between plaque/tumor and patch lesions of non-malignant cells that were mutually regulated in each patient, we only found LIFR (leukemia inhibitory factor receptor or CD118) in the EC-1 cluster to be downregulated (Fig. 4 B-C), the receptor for leukemia inhibitory factor (LIF) previously characterized as a tumor suppressor gene [29]. Functional differences in the relationship of the malignant clone with its microenvironment might, however, also occur on the level of receptor-ligand pairings where not always the same partner is affected across patients. Thus, we also assessed putative interactions between the malignant clone and non-malignant cells, as inferred by co-expression of ligand-receptor pairs (\( R \)) from CellPhoneDB [28] within each sample (Fig. 4 D-E, Table S5). Across patients, most ligand/receptor pairs were found for myeloid cells (dendritic cells, macrophages), followed by B cells and endothelial cells, while interaction scores of malignant cells with fibroblasts and keratinocytes were generally low (Fig. 4 D). In line with tumor cell - myeloid cell interactions,
Fig. 2 (See legend on previous page.)
immunofluorescence stainings confirmed the close vicinity of the expanded clone (as defined by specific TCR expression) with CD11c+ CD68+ dendritic cells and CD11c- CD68+ macrophages within MF lesional skin, both in plaque (Fig. 4 F) and patch lesions (data not shown), suggesting cell-to-cell contact between these populations. While some receptor/ligand pairs were present at high levels across all samples, such as CD74 - MIF on myeloid cells/malignant T cells, expression patterns were heterogeneous between patients (Fig. 4 E). The few receptor/ligand pairs that were consistently different between plaque/tumor vs. patch lesions included SELL - CD34 (malignant cells/lymphatic endothelial cells), CXCL12 - CXCR4 (fibroblasts/malignant cells), and CCL5 - CCR4 (cytotoxic T cells/malignant cells), all of which were downregulated with skin lesion progression (Fig. 4 E, Table S5). Most detected pairs, however, showed divergent regulation with lesion progression, further supporting the concept of patient-to-patient heterogeneity.

Corroborated of regulated genes in a case of γδ MF
In order to investigate whether our findings from three classic MF patients could be a more general mechanism among other forms of MF, we performed scRNA-seq in skin samples from a patient newly diagnosed with MF of a TCR γδ phenotype (MF318), who also presented with longstanding patches and newly developed plaques (Table 1, Fig. 5 A). Except for a minor population of melanocytes, both patch and plaque lesions harbored comparable cell clusters and numbers (Fig. 5 B-C, Table S6), with an abundance of TCR γδ positive T cells, that derived from a single clone (Fig. 5 D, labelled in red). By contrast, polyclonal T cells were of an αβ TCR phenotype (Fig. 5 D, labelled in green), containing CD4+ helper T cells, CD8A+ cytotoxic T cells, and FOXP3+ regulatory T cells (Fig. 5 E). Polyclonal γδ T cells were essentially absent (Fig. 5 D, labeled in blue). When calculating DEGs in plaque vs. patch lesions, we again found most DEGs to be present in monoclonal γδ T cell clusters (Fig. 5 F, Table S6-S7), that included cytotoxic markers such as GZMA, NKG7, GZMK, GZMB, CTSL, TYROBP (DAP12), and GZMH, but also the coiled-coil domain containing 85B (CCDC85B) previously associated with cancer proliferation and invasion [30], and the actin-binding PFN1 (Profilin-1) (Fig. 5 G, Table S6). Similar to above-mentioned αβ MF patients, the malignant clone in this γδ MF patient also showed significant decreases in CXCR4, CD69, HSPA1A, ZFP36, IL7R and TXNIP in plaque vs. patch lesions (Fig. 5 H, Table S6). Importantly, a decrease in these markers was absent in polyclonal T cell populations, namely CD4+ helper T cells, CD8A+ cytotoxic T cells, and FOXP3+ regulatory T cells, which showed relatively stable expression or even trends of increase in plaques (Fig. 5 H, Table S6). Other top downregulated markers in clonal cells included the actin-binding markers TMSB10 and ACTR3B, the CCL20 chemokine receptor CCR6, the apoptosis inhibitor BIRC3, cathepsin H (CTSH), and the TNF-induced anti-inflammatory mediator TNFAIP3 (Fig. 5 G). In non-T cells, we found highest numbers of DEGs in fibroblasts (Fig. 5 F, Table S7). The FB-3 cluster showed upregulation of genes involved in collagen biosynthesis and extracellular matrix organization (various COL genes, P4HB, ADAMTS2, LOXL2, LOXL1). In line with the concept of downregulated Th1 responses upon disease progression [9], we found decreased levels of the type-1-associated chemokines CXCL9 and CXCL10 in several cell populations in plaques vs. patches, including DC-1, EC-1, FB-1, MP-2, and MP-4 (Table S7). In sum, malignant γδ MF cells showed identical regulation of CXCR4, CD69, HSPA1A, ZFP36, IL7R and TXNIP as found in αβ MF clones, suggesting their involvement in disease progression across MF subtypes.

CD69, HSPA1A and ZFP36 are further elevated in patches of early-stage MF
As above-mentioned analyses were all performed in patients with advanced-stage disease, we next wanted
Fig. 3 (See legend on previous page.)
to compare our data with skin from patients with long-standing, early-stage disease, who had been showing an indolent clinical course over years to decades (Fig. 6 A, Table 1). T-cell subsets contained generally comparable cell counts in early-stage MF (9839 cells from 3 patients) and in patch lesions from MF patients with advanced-stage disease (11,136 cells from 3 patients), and both showed substantial numbers of proliferating cells (Fig. 6 B-C, Table S8). Interestingly, early-stage MF showed distribution of expanded clones primarily in clusters T1, T/NK, and the proliferating cluster, in contrast to malignant cells from patches of advanced-stage disease, which spread over several additional clusters in a more inconsistent fashion (Fig. 6 D). In line with decreasing levels in advanced plaque/tumor lesions, the markers CD69, HSPA1A and ZFP36 showed significantly higher expression levels in patches of early-stage MF in comparison to patches from advanced-stage MF (Fig. 6 E), while other T subsets (helper T cells, cytotoxic T cells, regulatory T cells) again did not consistently harbor such differences (Table S8). Genes that were present at significantly higher levels in malignant cells of patches from advanced vs. early-stage MF included the lymph node homing markers CCR7, SELL and CD27 [31], the CTCL markers IGF2L2 and KIR3DL2 [32, 33], the helper T cell growth factor IL16 that has previously been implicated in recruitment of malignant cells to MF lesions [34], and the lymphocyte developmental marker IKZF2 [35] (Fig. 6 F). Markers predominantly found in tumor cells of early-stage MF lesions included cytotoxic molecules such as GNLY, GZMA, GZMB and GZMH, as well as a broad array of inflammatory cytokines/chemokines such IFNG, CCL4, CCL1, CSF2, CCL3, CCL20, IL26, CXCL1, and XCL2 (Fig. 6 F). In benign cells, by contrast, cytotoxic and associated mediators (GZMK, IFNG, GZMH, NKG7, GZMA) were upregulated in cytotoxic T cells of advanced-stage, and not early-stage patches (Fig. 6 G). Early-stage lesions, however, exerted increased expression of the NF-κB inhibitor NFKBIA and the anti-angiogenic chemokine CXCL14 in helper, cytotoxic and regulatory T cells (Fig. 6 G-I). Among non-T cells (Fig. S4A-B), we found increased levels of the Th2-associated chemokine CCL17 in macrophages and LAMP3+ mature DC-3, and concomitant decreases in the Th1-associated markers CXCL9 and CXCL10 in dendritic cells and macrophages of advanced-stage lesions (Table S9), corroborating the concept of a shift in Th2/Th1-associated markers during disease progression in MF [9].

Phenotypic changes in follow-up samples during disease exacerbation
To better understand the dynamics of disease progression in MF, we followed patients over time and performed new biopsies upon phenotypic change or treatment response, and integrated the new data sets with the existing scRNA-seq data, separately for each individual. After 4 cycles of brentuximab vedotin resulting in a complete response and ongoing treatment with extracorporeal photopheresis (ECP), patient MF309 experienced progressive disease with generalized ulcerating tumors 9 months after initial sampling (Fig. 7 A). The single malignant clone (Fig. 7 B-C). Tables S10-S12 maintained decreased expression of CXCR4, CD69, HSPA1A, and ZFP36 in the follow-up lesion, while IL7R and TXNIP showed a trend of increase towards levels.
Fig. 4 (See legend on previous page.)
found in the initial patch lesion (Table S10, Fig. S5A). Malignant cells of the follow-up lesion were characterized by increases in the pro-tumorigenic mediator LTB [36], as well as NK-associated receptor KLRC1 (NKG2) and CD74, both known to promote T cell survival, while cytotoxic chemokines XCL1 and XCL2 were decreased (Table S10). Among non-T cells, there was an increase in B cells with advancement of disease, which were virtually absent in patch lesions (Fig. 7 B-C). In the ulcerated tumor, B cells showed increased markers associated with type-2 responses such as CCL17, IL4R, and decreases in interferon-stimulated genes (IFI44L, STAT1, IFITM1, MX1, IRF1, Fig. 7 D, Table S12).

Together with decreases in IFNG expression in the benign proliferating TC-11 cluster (Table S12), these findings were consistent with the established concept of decreasing type-1 and increasing type-2 skewing in progressing MF lesions [9].

In contrast to patient MF309, patient MF311 did not develop tumors, but erythroderma 7 months after initial sampling, despite combination treatment with ECP, chlorambucil and systemic glucocorticoids (Fig. 7 E). This follow-up lesion showed absence of three T cell clusters, namely clusters TC-6 and TC-8 (found in the initial patch lesions) and TC-7 (found only in the plaque lesion; Fig. 7 F-G). Both TC-6 and TC-8 were rich in CCR7 expression (Table S13). CCR7 is a chemokine receptor initially described in naïve and T memory stem cells [37] and a characteristic marker for recirculating T cells that are typically found in MF lesions with ill-defined as opposed to sharply demarcated borders [22], consistent with the clinical (Fig. 7 A, E) and molecular phenotype (Fig. 7 H) of malignant clones in our patients.

TC-7, primarily present in the plaque lesion, was characterized by increased levels of PEN1 (Table S13), similar to what we observed in γδ MF plaques (Fig. 5 G), and showed elevated levels of the T-cell activation marker ITM2A and the cutaneous lymphoma marker IGLL2 [32] (Table S13). Overall frequencies of monoclonal vs. polyclonal T cells remained relatively stable over time, and the majority of malignant cells expressed the TCR-α chain CAGKTSYDKVIF (Fig. 7 G). However, a second TCR-α chain CAVSEGGAQKLVF increased from 6.8 and 1.2% in initial patch and plaque lesions, respectively, to 40.1% of TCR-α+ malignant clones in erythrodermic lesions (Fig. 7 G). Nevertheless, both TCR-α chains (labelled TCRA1 in red, and TCRA2 in purple in Fig. 7 G) showed pairing of the same TCR-β chain CASS-FGGVSLHF (data not shown), suggesting that both TCRA1+ and TCRA2+ cells represent the same clone, albeit with differing levels of allelic exclusion [38]. In line, there was only a limited number of DEGs present at a low log fold change when comparing TCRA1 with TCRA2 clones in the follow-up lesion (Table S13, “TRA_CAG vs. CAV”). Low expression of CXCR4, CD69, ZFP36 and TXNIP was maintained upon disease exacerbation, while IL7R and HSPA1A reverted to the levels detected in initial patch lesions (Fig. S5B). In erythroderma, malignant cells showed strong increases in CXCL13 compared to both patch and plaque lesions (Fig. 7 I-J, Table S13), previously described to be highly upregulated in Sézary cells [39]. Among benign cells, there was a shift towards a more type-2-biased immune microenvironment, as reflected by increases in CCL17 and CCL18 expression in myeloid cells, and decreases in the type-1-associated chemokines CXCL9 and CXCL10 in myeloid cells, fibroblasts and endothelial cells (Tables S14-S15). Increased inflammatory keratinocyte responses were reflected by elevated levels of inflammatory keratins KRT6A and KRT16 (Tables S14-S15). Taken together, disease exacerbation was associated with increased type-2 responses in both patients, while initial overexpression of CCR7 preceded erythroderma, but not tumor formation.

**Downregulation of CXCR4, CD69, HSPA1A, ZFP36, IL7R and TXNIP is reverted in malignant clones of clinically unaffected skin of MF patients**

We also followed patient MF312, who received topical chlormethine hydrochloride 160 μg/g gel formulation
Fig. 5 (See legend on previous page.)
QD. After 5 weeks of treatment, several of his MF lesions had resolved, and we took a biopsy from such a treated lesion (Fig. S6A-B, Table S16). Despite complete clinical clearance, general decreases in inflammatory mediators (Tables S17-S18), and a substantial reduction in overall T-cell counts, we were surprised to still find 20.6% of all TCR+ cells to be of the malignant clone (labelled in red in Fig. S6C), harboring the same TCR-α chain CALMDSYKLIF as observed in the initial patch and plaque lesion. To assess whether the presence of a malignant clone is a general phenomenon in clinically unaffected skin of MF patients, we profiled lesional and nonlesional skin of seven patients (from patients MF309, MF311 and MF312, as well as additional patients P65, P73, P84 and P90), and compared results to four healthy control individuals (Fig. 8, Fig. S7-S8, Table 1). While clusters containing CD4+ helper T cells (“T1”), CD8+ cytotoxic T cells (“Tc”), FOXP3+ regulatory T cells (Treg), NK cells (“NK”) and a small group of T3 “admixed with CD3δ- KLRD1- KLRB1+ XCL1+ innate lymphoid cells [40] (ILC, Fig. S7A-D) remained relatively stable across all three groups, we noticed a decrease in proliferating cells (“T prolif”) in nonlesional MF, with almost absence in healthy control skin (Fig. 8 A-C, Table S19). Similarly, a population “T2” of IGFL2+ KIR3DL2+ cells was present at substantial levels only in lesonal, but not in nonlesional MF or healthy control skin (Fig. 8 A, C, Fig. S7E-F). We found considerable numbers of malignant cells to be present in five out of seven nonlesional MF samples, with frequencies ranging from 20.8 to 80.5% of all TCR+ cells (Fig. 8 D-E). In contrast to MF, top expanded clone frequencies in the four healthy control samples were as low as 1.7 to 7.0% among respective TCR+ cells (Fig. 8 F), consistent with an overall polyclonal T cell pattern. Frequencies of malignant vs. polyclonal cells per cluster were largely comparable between lesional and nonlesional samples, except for decreases in malignant proliferating cells in nonlesional skin (Fig. 8 G). When assessing the CXCR4, CD69, HSPA1A, ZFP36, IL7R and TXNIP gene panel, we found levels of all 6 markers to be increased in nonlesional vs. lesional MF in malignant cells, but not in other lymphoid cell subsets (helper T cells, regulatory T cells, cytotoxic T cells, and NK cells; Fig. 8 H, Fig. S7G, Table S19). Numbers of ILCs other than NK cells (Fig. S7A-D) were too small to conduct meaningful calculations. Most DEGs between lesional and nonlesional MF were found in cells of the malignant clone (Fig. 8 I, Table S19), with upregulation of CXCL13, IGFL2, CORO1B, GIMAP4, EPHX2, HACD1, and ATF5 in lesional vs. nonlesional MF (Fig. 8 I). CXCL13 was also strongly upregulated in helper and cytotoxic, but not regulatory T cells (Fig. 8 I). Genes significantly upregulated in helper T cells included the central memory markers SEL and CCR7, the nucleotide-binding GIMAP7 and GIMAP4, lymphotxin beta LTB and the interleukin IL16. Lesional regulatory T cells were characterized by increased levels of IL2RA, LTB, GIMAP7, GIMAP4, but decreases in granulysin GNLY (Fig. 8 I). Lesional cytotoxic T cells showed upregulation of the co-stimulatory molecule TNFRSF9 (CD137), the cytotoxic cytokines XCL2 and XCL1, as well as SEL, and decreases in the macrophage inflammatory protein CCL4, a chemokine that was also downregulated in NK cells (Fig. 8 I, S7H). When comparing nonlesional MF with healthy control samples, we found cytotoxicity-associated molecules (GZMA, GZMK, NKG7, GZMH, GZMB, IFNG, CCL5) still being upregulated in cytotoxic T cells (Fig. S7I, Table S20), while other cell types only showed few regulated genes, such as elevated CTLA4 in helper T cells (Fig. S7J). These data suggest some maintained cytotoxic activity in CD8+ cytotoxic T cells of nonlesional MF skin. Among non-T cells, we found decreased frequencies of B cells in nonlesional vs. lesional MF, being essentially absent in healthy control skin (Fig. S8A-C, Table S21). Their continuous increase from early to late-stage MF might suggest a role during disease progression (Fig. S8D). B cells in lesional MF displayed increased levels of type 2-associated chemokines CCL17 and CCL18, LTB,
Fig. 6 (See legend on previous page.)
**TMSB4X** (Thymosin beta-4) compared to nonlesional MF (Table S22). Other cell types essentially absent in healthy control samples included proliferating fibroblasts FB-6, KRT16+ inflammatory keratinocytes KC-6, and LAMP3+ mature DC-3 (Fig. S8C). Compared to healthy control skin, nonlesional MF still harbored increased levels of type-2 associated chemokines such as CCL13 and CCL18 in macrophages, type-1 associated chemokines CXCL9 and CXCL10 in dendritic cells, as well as activation markers such as MX1 and S100A8 in keratinocytes (Fig. S8E-F, Table S23), suggesting some retained inflammatory environment, despite the absence of clinically visible MF involvement.

**Discussion**

Using scRNA-seq combined with αβ and γδ TCR sequencing, we identified a panel of markers that were consistently downregulated in the malignant clone of progressing MF skin lesions. While usual clinical staging of MF (IA-IVB) does not discriminate between patches or plaques, there is a significant difference documented regarding survival rates of patients with early-stage disease presenting with patches only (TNM stage T1a/ T2a) compared to those with patches and plaques (TNM stage T1b/T2b) [41]. Our in-depth analysis of patients with advanced-stage disease revealed differences between such flat (patch) and palpable (plaque/tumor) lesion types which might reflect mechanisms contributing to disease progression and impact on overall prognosis. Consistently, the markers that we identified (CXCR4, CD69, HSPA1A, ZFP36, IL7R and TXNIP) have all been previously described to be either involved in skin homing, cell growth or cancer development. The chemokine receptor CXCR4 is widely expressed on various cell types, and binding of its ligand CXCL12 (stromal cell-receptor CXCR4 is widely expressed on various cell types, and binding of its ligand CXCL12 (stromal cell-receptor CXCR4 is widely expressed on various cell types, and binding of its ligand CXCL12 (stromal cell-receptor CXCR4 is widely expressed on various cell types, and binding of its ligand CXCL12) triggers multiple signaling pathways involved in cell migration, hematopoiesis, bone marrow retention, and tissue homing [42, 43]. Other CXCR4 ligands include ubiquitin, which can act as an anti-inflammatory immune modulator and endogenous opponent of proinflammatory DAMPs [44], and the inflammatory cytokine macrophage migration inhibitory factor (MIF) [42]. CXCR4 has been found in MF cells and tumor-infiltrating lymphocytes [45], but reports on its expression levels in conjunction with distinct disease stages have been contradictory [46–48]. Importantly, the contribution of CXCR4 to skin homing and retention has been shown for Sézary cells [49] and skin-residing acute myeloid leukemia (AML) cells in patients with cutaneous metastases [50]. Thus, decreased expression of CXCR4 in malignant MF cells upon disease progression might facilitate lymphoma cell mobility, or even dissemination. This effect is likely supported by concomitant decreases in CD69, a marker whose expression is associated with prolonged tissue retention of T_{RM} in the skin [51]. While CD69 has initially been described as an early marker of lymphocyte activation, its role seems to be more complex, also involving immunoregulatory functions [52]. Importantly, decreased CD69 levels on lymphoma cells have previously been found in more Th2-skewed CTCL lesions [53], a phenotype associated with progressing disease [9].

The thioredoxin-interacting protein TXNIP can mediate oxidative stress, inhibit cell proliferation, induce apoptosis [54], and has also been described as an inhibitor of NK cell-mediated macrophage activation [55]. However, decreases of TXNIP in advancing lesions is consistent with its putative tumor suppressor function [56], as forced expression inhibits malignant proliferation in CTCL-derived cell lines [57]. Tristetraprolin/TTP (ZFP36), a TIS11 family member, promotes the degradation of several cytokines via binding to AU-rich elements in the 3’ untranslated regions of their mRNA. TTP is known to act as a tumor suppressor and key regulator of inflammatory responses [58, 59]. Decreased TTP levels have been demonstrated in malignancies with MYC involvement, and restoring its levels counteracted cancer development [60].

---

**Fig. 7** Characterization of follow-up lesions during disease exacerbation. **A** Pictures of MF lesions of patient MF309 showing initial flat (patch) and palpable (tumor), as well as follow-up (ulcerated tumor) lesions. Black circles indicate the location where the respective biopsy was taken from. **B** UMAP of 20,944 cells integrated from these three MF309 skin biopsies according to similarity of their transcriptome, resulting in 25 different color-coded clusters. **C** UMAP plots of samples colored according to most common monoclonal TCR (red), polyclonal αβ TCRs (green) and cells without detectable TCR (grey). Percentages denote frequencies of malignant cells among all TCR+ cells for each plot. **D** Volcano plot showing differentially expressed genes in B cells in follow-up vs. tumor lesions. **E** Pictures of MF lesions of patient MF311 showing initial patch and plaque, as well as follow-up lesions (erythroderma). Black circles indicate the location where the respective biopsy was taken from. **F** UMAP of 40,020 cells integrated from three MF311 skin biopsies according to similarity of their transcriptome, resulting in 26 different color-coded clusters. **G** UMAP plots of samples colored according to most common monoclonal TCRs TCR1 (red), TCR2 (purple), polyclonal αβ TCRs (green) and cells without TCR detected (grey). Percentages denote frequencies of malignant cells among all TCR+ cells for each plot. **H** Violin plots showing distribution of normalized CCR7 gene expression levels of benign and malignant T cells in the respective skin lesions. **I** Volcano plots of differentially expressed genes within the malignant clone of MF311 comparing follow-up with patch and plaque lesions, respectively. **J** T cells; **K** B cells; **L** keratinocytes; **M** fibroblasts; **N** dendritic cells; **O** macrophages; **P** myofibroblasts; **Q** endothelial cells; pDC plasmacytoid dendritic cells.
Fig. 7 (See legend on previous page.)
Thus, decreasing levels of TTP/ZFP36 and TXNIP in malignant clones indicate loss of tumor-suppressive functions.

Keratinocyte-derived IL-7 has been described as a potent growth factor for CTCL [61–63], and regulation of its receptor IL7R has previously been associated with IL-2 cytokine signaling [64, 65]. The specific decrease in IL7R that we found in malignant clones, but not benign bystander cells, might therefore indicate a change in cytokine responsiveness over time. In line, malignant MF cells are considered more and more cytokine independent with advancing disease, and IL-7 might thus only impact on malignant cells in early, but not advanced disease stages [66].

The role for HSPA1A, coding for heat shock 70 kDa protein 1 (HSP72), is less obvious. HSP72 is involved in DNA repair and the guidance of protein folding as a chaperone [67], has previously been reported to be increased in aggressive versus non-aggressive MF [68], and to dampen T cell mediated inflammatory reactions in vitro [69]. However, this gene product is believed to have a dual role in cancer cells, as intracellular HSP72 protects malignant cells by interfering with apoptotic pathways, while membrane-associated and extracellular HSP72 can elicit antitumor immune responses [70]. Given these discrepancies, the exact role of this mediator in MF remains to be elucidated. Nevertheless, the fact that CXCR4, CD69, HSPA1A, ZFP36, IL7R and TXNIP were concomitantly decreased in TCR-αβ and TCR-γδ tumor cells of advanced MF lesions, and the observation that CD69, HSPA1A and ZFP36 were increased in early-stage MF patients, suggests that this marker panel reflects a general mechanism of skin lesion progression in MF in a continuous fashion from longstanding indolent to more aggressive late-stage disease. However, the common denominator regulating these marker changes in MF cells remains to be elucidated. Much to our surprise, five out of seven MF patients harbored substantial numbers of malignant cells also in clinically uninvolved skin. In line with a potentially more “silenced” phenotype, these nonlesional tumor cells harbored elevated levels of CXCR4, CD69, HSPA1A, ZFP36, IL7R and TXNIP when compared to matched lesional skin. Whether there are differences in gene expression between areas of treated MF (i.e. “postlesional”) vs. locations that have never been clinically involved (“never-lesional”) skin needs to be determined in larger patient cohorts. Nevertheless, this finding sheds a new light on future curative CTCL treatment approaches, that will need to take into account a tumor cell burden well beyond merely visibly involved skin. Importantly, we found a population of IGFL2+ KIR3DL2+ tumor cells that was largely absent in nonlesional MF or healthy control skin, which might be crucially involved in the formation of actively inflamed, clinically visible MF lesions. In line, IGFL2 has previously been described as a marker overexpressed in Sézary cells [32], and KIR3DL2 [71] is currently being investigated in clinical trials as therapeutic target for CTCL, showing early promising results [72].

In contrast to the expanded clone, we did not find consistent transcriptomic regulation within the microenvironment across patients, and receptor/ligand pairs of lymphoma cells with benign cells were expressed in a very heterogeneous fashion. Yet, we found some limited downregulation of the CXCL12-CXCR4 and CCL5-CR4 immune axes in advancing lesions, which might indicate decreasing interaction with fibroblasts and cytotoxic T cells, respectively. Interestingly, early-stage MF tumor cells showed a more cytotoxic phenotype when compared to advanced-stage MF patch lesions. In line, indolent lymphomas such as lymphomatoid papulosis have been described to preferentially express such molecules in contrast to more aggressive CTCL [73], suggesting a potential involvement in indolent lesion behavior. In line with previous publications, we found a shift towards type-2 inflammation in advancing lesions, as well as increasing

(See figure on next page.)

**Fig. 8** Comparison of lesional with nonlesional MF and healthy control skin. A UMAP of 32,958 subclustered cells from lymphocyte clusters TC-1, TC-2, TC-3/NK and TC-4 of Fig. S8, integrated from 7 MF patients with lesional and nonlesional biopsies, and 4 healthy control samples, according to similarity of their transcriptome, resulting in 8 different color-coded clusters, split according to tissue of origin. B Feature plots showing expression of selected T cell and NK cell marker genes. Normalized expression level for each cell is color-coded (red) and overlaid onto UMAP plots. C Frequencies of cell clusters within groups. D-E UMAP plots of individual patients colored according to most common monoclonal (red) and polyclonal (green) αβ TCR, cells without TCR are displayed in grey. Percentages denote frequencies of malignant cells among all TCR+ cells for each plot. F UMAP of four healthy control biopsies; the single most frequent clone for each sample is depicted in blue (P112), orange (P115), purple (P116) or yellow (P121); all other TCR+ cells are shown in green, and cells without detectable TCR in grey. G Distribution of the malignant clone (red), polyclonal TCR+ cells (green), and cells without detectable TCR, as percentages for each cluster in lesional and nonlesional biopsies. H Violin plots showing distribution of normalized gene expression levels in nonlesional (green), lesional (red) and healthy control skin (blue) for the top expanded αβ TCR clone, as well as helper T cells, regulatory T cells, and cytotoxic T cells. I Volcano plot showing differentially expressed genes (DEGs) of the malignant clone, as well as polyclonal helper, cytotoxic and regulatory T cells between lesional and nonlesional MF biopsies. Differential gene expression was defined as log fold change >0.25 as calculated by logistic regression and Bonferroni correction. Regulatory T cells: FOXP3+ cells with polyclonal TCRs. Cytotoxic T cells: CD8A+ FOXP3- cells with polyclonal TCRs. Helper T cells: CD4+ FOXP3- cells with polyclonal TCRs. UMAP: Uniform Manifold Approximation and Projection.
Fig. 8 (See legend on previous page.)
numbers of B cells, which might be relevant players for lesion progression [9, 74]. We were surprised not to find significant regulation of checkpoint inhibitors or their ligands in our advanced-stage patch vs. plaque/tumor analyses, as PD1 gene mutations have been described to drive aggressive behavior in CTCL [75]. Nevertheless, we found CTLA4 to be strongly upregulated in helper T cells of nonlesional MF, which might have a role in anti-inflammatory properties of clinically unaffected MF skin. We also found some residual inflammation in nonlesional MF vs. healthy control skin, which might also have a role in tumor cell control, a phenomenon that needs further elucidation in larger patient cohorts.

Conclusions
Taken together, we identified a characteristic panel of markers associated with cutaneous disease progression in MF. Such potential drivers of disease might constitute ideal targets for future drug therapy with a new treatment strategy of preventing disease progression by preserving a more indolent cancer biology.

Abbreviations
CTCL: Cutaneous T-cell lymphoma; MF: Mycosis fungoides; TCR: T-cell receptor; Treg: Tissue resident memory T cell; scRNA-seq: Single-cell RNA sequencing; TCRA: T-cell receptor alpha locus; TCRB: T-cell receptor beta locus.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12943-021-01419-2.

Acknowledgements
We thank the Biomedical Sequencing Facility (BSF) at CeMM for assistance with next-generation sequencing.

Authors’ contributions
Conceptualization, P.M.B., C.J., M.F., K.R.; Software and Formal Analysis, K.R., F.H., N.A.; Visualization: K.R., F.H., F.M.T.; Investigation, M.F., L.E.S., C.J., N.A., H.K., W.M.B.; Resources, G.S., W.W.; Writing – Original Draft P.M.B, C.J., K.R., F.H.; Writing – Review & Editing M.F., G.S., W.W., L.E.S., N.A., W.M.B.; Project Administration & Supervision, P.M.B., C.J., M.F.; Funding Acquisition, P.M.B. The authors read and approved the final manuscript.

Funding
This work was funded by a research grant to P.M.B from the Austrian Science Fund (grant number KLI 849-B). MF was supported by a special research grant of the Austrian Science Fund (grant number SFB-F61.03).

Availability of data and materials
The 10X Genomics datasets generated during this study is publicly available via Gene Expression Omnibus GSE173205.

Declarations
Ethics approval and consent to participate
The study was conducted under a protocol approved by the Ethics Committee of the Medical University of Vienna, Austria (EK 1360/2018).

Consent for publication
Not applicable.

Competing interests
CJ is an employee of the Medical University of Vienna, and has received personal fees from LEO Pharma, Pfizer, Recordati Rare Diseases, Eli Lilly and Company, Novartis, Takeda, Mallinckrodt/Therakos, AbbVie, Janssen, Sandoz, Kyowa Kirin and Almirall independently from this work. CJ is an investigator for Eli Lilly and Company, LEO Pharma, Novartis, and 45C (grant paid to her institution). GS received personal fees from Boehringer Ingelheim, Sanofi-Genzyme, Almirall, and Novartis. WW is an employee of the Medical University of Vienna and has received personal fees from LEO Pharma, Pfizer, Sanofi Genzyme, Eli Lilly, Novartis, Boehringer Ingelheim, AbbVie, and Janssen. WMB is an employee of the Medical University of Vienna and has received personal fees from Takeda, Abbvie, GSK/Viiv and Gilead. PMB is an employee of the Medical University of Vienna, and has received personal fees from LEO Pharma, Pfizer, Sanofi Genzyme, Eli Lilly, Novartis, Celgene, UC B Pharma, Biotest, Boehringer Ingelheim, AbbVie, Amgen, Arena Pharmaceuticals, GSK and Regeneron independently from this work. PMB is an investigator for Novartis (grant paid to his institution). The rest of the authors declare that they have no relevant conflicts of interest.

Author details
1 Department of Dermatology, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria. 2 St. Anna Children’s Cancer Research Institute (CCRI), Zimmermannplatz 10, 1090 Vienna, Austria.

Received: 26 May 2021 Accepted: 28 August 2021
Published online: 28 September 2021

References
1. Brunner PM, Jonak C, Knobler R. Recent advances in understanding and managing cutaneous T-cell lymphomas. F1000Res. 2020;9:F1000 Faculty Rev-331.
identifies aggressive early-stage mycosis fungoides. Sci Transl Med. 2018;10(440):eaar5894.

24. Scarsbrick JJ, Hodak E, Bagot M, Stranzenbach R, Stadler R, Ortiz-Romero PL, et al. Blood classification and blood response criteria in mycosis fungoides and Sezary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force. Eur J Cancer. 2018;83:47–56.

25. Kazazian H, Haffani Y, Ng D, Lee CMM, Johnston W, Kim M, et al. FAM46C/TENTSC functions as a tumor suppressor through inhibition of PI4K activity. Commun Biol. 2020;3(1):448.

26. Litvinov IV, Netchiporouk E, Cordeiro B, Dore MA, Moreau L, Pehr K, et al. The use of transcriptional profiling to improve personalized diagnosis and Management of Cutaneous T-cell lymphoma (CTCL). Clin Cancer Res. 2015;21(12):2820–9.

27. van Kester MS, Borg MK, Zoutman WH, Oulousting JJ, Jansen PM, Dreef EJ, et al. A meta-analysis of gene expression data identifies a molecular signature characteristic for tumor-stage mycosis fungoides. J Invest Dermatol. 2012;132(8):2050–9.

28. Efremova M, Vento-Tormo M, Teichmann SA, Vento-Tormo R. Cell-PhoneDB: inferring cell-cell communication from combined expression of multi-subunit ligand-receptor complexes. Nat Protoc. 2020;15(4):1484–506.

29. Tomida M. Structural and functional studies on the leukemia inhibitory factor receptor (LIF-R): gene and soluble form of LIF-R, and cytoplasmic domain of LIF-R required for differentiation and growth arrest of myeloid leukemic cells. Leuk Lymphoma. 2003;7:5–6175–27.

30. Feng Y, Gao Y, Yu J, Jiang G, Zhang X, Lin X, et al. CCDC15B5 promotes non-small cell lung cancer cell proliferation and invasion. Mol Carcinog. 2019;58(1):126–34.

31. Campbell JJ, Clark RA, Watanabe R, Kupper TS. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood. 2010;116(5):767–71.

32. Booken N, Gratchev A, Utkal J, Weiss C, Yu X, Qadoumi M, et al. Sezary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CD01 and DNM3. Leukemia. 2006;20(2):299–305.

33. Roelens M, de Masson A, Ram-Wolff C, Maki G, Cayuela JM, Marie-Cardine A, et al. Revisiting the initial diagnosis and blood staging of mycosis fungoides and Sezary syndrome with the HIR3DL2 marker. Br J Dermatol. 2020;182(6):1415–22.

34. Tuzova M, Richmond J, Wolowitz D, Cureil-Lewandrowski C, Chaney K, Kupper T, et al. CCR4+ T-cell recruitment to the skin in mycosis fungoides: potential contributions by thymic stromal lymphopoietin and interleukin-16. Leuk Lymphoma. 2015;56(2):440–9.

35. Borcherding N, Voigt AP, Liu V, Link BK, Zhang W, Jabbar A. Single-cell profiling of cutaneous T-cell lymphoma reveals underlying heterogeneity associated with disease progression. Clin Cancer Res. 2019;25(10):2996–3005.

36. Tracey L, Spiteri I, Ortiz P, Lawler M, Piris MA, Villuendas R. Transcriptional response of T cells to IFN-alpha: changes induced in IFN-alpha-sensitive and resistant cutaneous T cell lymphoma. J Interf Cytokine Res. 2004;24(3):185–95.

37. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;398(6724):706–12.

38. Dupic T, Marcou Q, Walczak AM, Mora T. Genesis of the alphabeta T-cell receptor repertoire. PLoS Comput Biol. 2019;15(3):e1006674.

39. Picchio MC, Scala E, Pompeoni D, Caprini E, Frontini M, Angelucci I, et al. CXCL13 is highly produced by Sezary cells and enhances their migratory ability via a synergistic mechanism involving CCL19 and CCL2L1 chemokines. Cancer Res. 2008;68(17):7137–46.

40. Alkon N, Bauer W, Krausgruber T, Goh L, Griss J, Nguyen V, et al. Single-cell analysis reveals innate lymphoid cell lineage infidelity in atopic dermatitis. J Allergy Clin Immunol. 2021; in press.

41. Agar NS, Wedgworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010;28(31):4730–9.

42. Bianchi ME, Mezzapelle R. The chemokine receptor CXCR4 in cell proliferation and tissue regeneration. Front Immunol. 2020;11:2109.
43. Karpova D, Rettig MP, DiPersio JF. Mobilized peripheral blood: an updated perspective. F1000Res. 2019;8:F1000 Faculty Rev-2125.

44. Pawlig L, Kläsen C, Weber C, Bernhagen J, Noels H. Diversity and interconnections in the CXCR4 chemokine receptor/ligand family: molecular perspectives. Front Immunol. 2015;6:429.

45. Kallinich T, Mulche JM, Qin S, Steiny W, Audring H, Kroczenka R. Chemokine receptor expression on neoplastic and reactive T cells in the skin at different stages of mycosis fungoides. J Invest Dermatol. 2003;121(5):1045–52.

46. Maj J, Janowska-Ksurs AM, Halon A, Wozniak Z, Plomer-Niezgoda E, Reich A. Expression of CXCR4 and CXCL12 and their correlations to the cell proliferation and angiogenesis in mycosis fungoides. Postepy Dermatol Alergol. 2015;32(6):437–42.

47. Daggett RN, Kurata M, Abe S, Onishi I, Miura K, Sawada Y, et al. Expression dynamics of CXCL12 and CXCR4 during the progression of mycosis fungoides. Br J Dermatol. 2014;171(4):722–31.

48. Aronovich A, Moyal L, Gorovitz B, Amitay-Laish I, Naveh HP, Forer Y, et al. Cancer-associated fibroblasts in mycosis Fungoides promote tumor cell migration and drug resistance through CXCL12/CXCR4. J Invest Dermatol. 2021;141(3):619–27 e2.

49. Narducci MG, Scala E, Bresin A, Caprini E, Picchio MC, Remotti D, et al. Skin homing of Sezary cells involves SDF-1–CXCR4 signaling and down-regulation of CD26/dipeptidylpeptidase IV. Blood. 2006;107(3):1108–15.

50. Faijai CM, Willemze R, Revesz T, Balzarolo M, Tensen CP, Hoogeboom M, et al. Chemokine/chemokine receptor interactions in extramural lymphoma of the skin in childhood AML: differential roles for CCR2, CCR5, CXCR4 and CXCR7. Pediatr Blood Cancer. 2010;55(2):344–8.

51. Mackay LK, Braun A, Macleod BL, Collins N, Tebartz C, Bedou S, et al. Cutting edge: CD69 interference with sphingosine-1-phosphate receptor function regulates peripheral T cell retention. J Immunol. 2015;194(5):2059–63.

52. Yu L, Yang F, Zhang F, Guo D, Li L, Wang X, et al. CD69 enhances immunosuppressive function of regulatory T-cells and attenuates colitis by prompting IL-10 production. Cell Death Dis. 2018;9(9):905.

53. Dorfman DM, Shihazi A. CD69 expression correlates with expression of other markers of Th1 T cell differentiation in peripheral T cell lymphomas. Hum Pathol. 2002;33(3):330–4.

54. Chung Y, Ning J, Cao W, Wang S, Du T, Jiang J, et al. Research Progress of TXNIP and promotes tumour cell proliferation in mycosis Fungoides. Acta Derm Venereol. 2020;100(16):adv00270.

55. Kim DO, Byun JH, Kim WS, Kim MJ, Choi JH, Kim H, et al. TXNIP regulates natural killer cell-mediated innate immunity by inhibiting IFN-gamma production during bacterial infection. Int J Mol Sci. 2020;21(24):9499.

56. Lindahl LM, Gauld M, Emmanuel T, Thomsen EA, Hu T, Rittig AH, et al. MicroRNA-106b regulates expression of the tumour suppressors p21 and TXNIP and promotes tumour cell proliferation in mycosis Fungoides. Acta Derm Venerol. 2020;100(16):adv00270.

57. Stolearenco V, Leving TB, Nielsen HM, Lindahl L, Fredholm S, Kongsbak-Wismann M, et al. The Thoredoxin-interacting protein TXNIP is a putative tumour suppressor in cutaneous T-cell lymphomas. Dermatology. 2021;237(2):283–90.

58. Guo J, Qu H, Chen Y, Xia J. The role of RNA binding protein tristetraprolin in cancer and immunity. Med Oncol. 2017;34(2):196.

59. Sneezum L, Eislmayr K, Dworak H, Sedlyarov V, Le Heron A, Ebner F, et al. Context-dependent IL-1 mRNA-destabilization by TTP prevents Dysregulation of immune homeostasis under steady state conditions. Front Immunol. 2020;11:1398.

60. Rouenbeher RJ, Fallahi M, Yang C, Steeves MA, Li W, Doherty JR, et al. Tristetraprolin impairs myc-induced lymphoma and abolishes the malignant state. Cell. 2012;150(3):563–74.

61. Bagot M, Charue D, Boullad ML, Gaulard P, Revuz J, Schmitt C, et al. Interleukin-7 receptor expression in cutaneous T-cell lymphomas. Br J Dermatol. 1996;135(4):572–5.

62. Dalloul A, Larche L, Bagot M, Mossalayi MD, Fournade C, Thacker DJ, et al. Interleukin-7 is a growth factor for Sezary lymphoma cells. J Clin Invest. 1992;90(3):1054–60.

63. Hahtola S, Tuomela S, Elo L, Hakkinen T, Karenko L, Nedoszytko B, et al. Th1 response and cytotoxicity genes are down-regulated in cutaneous T-cell lymphoma. Clin Cancer Res. 2006;12(16):4812–21.

64. Doms H, Wolslegel K, Lin P, Abbas AK. Interleukin-2 enhances CD4+ T cell memory by promoting the generation of IL-7Rα-expressing cells. J Exp Med. 2007;204(3):547–57.

65. Xue HH, Kovanen PE, Pise-Massison CA, Berg M, Radvich MF, Brady JN, et al. IL-2 negatively regulates IL-7 receptor alpha chain expression in activated T lymphocytes. Proc Natl Acad Sci U S A. 2002;99(21):13759–64.

66. Netchiporouk E, Litvinov IV, Moreau L, Gilbert M, Sasseville D, Duvic M. Derepression in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression. Cell Cycle. 2014;13(21):3331–5.

67. Singh R, Kolvraa S, Bross P, Christensen K, Bathum L, Gregersen N, et al. Anti-inflammatory heat shock protein 70 genes are positively associated with human survival. Curr Pharm Des. 2010;16(7):796–801.

68. Lernchak D, Baneejee S, Digambar SS, Hood BL, Conrads TP, Jedsch J, et al. Therapeutic and prognostic significance of PARP-1 in advanced mycosis fungoides and Sezary syndrome. Exp Dermatol. 2018;27(2):188–90.

69. Stocki P, Wang XN, Dickinson AM. Inducible heat shock protein 70 reduces T cell responses and stimulatory capacity of monocyte-derived dendritic cells. J Biol Chem. 2012;287(15):12387–94.

70. Vostakolaia MA, Hatami-Baroogh L, Babaei G, Molavi O, Kordi S, Abdollahi-zadeh J. Hsp70 in cancer: a double agent in the battle between survival and death. J Cell Physiol. 2021;236(5):4240–44.

71. Sun J, Wang Y. KIR3DL2 in cutaneous T-cell lymphoma: from a promising biomarker to a potential therapeutic target. Br J Dermatol. 2020;182(6):1325–6.

72. Bagot M, Porcu P, Marie-Cardine A, Battistella M, William BM, Vermeer M, et al. IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. Lancet Oncol. 2019;20(8):1160–70.

73. Nevala H, Karenko L, Vakeva L, Ranki A. Proapoptotic and antiapoptotic markers in cutaneous T-cell lymphoma skin infiltrates and lymphomatoid papulosis. Br J Dermatol. 2001;145(6):928–37.

74. Nielsen PR, Eriksen JO, Sorensen MD, Wehkamp U, Lindahl LM, Bzorek MK, et al. IL-12 regulates peripheral T cell responses and stimulates cytokine production. J Immunol. 2004;173(10):6228–37.

75. Park J, Daniels J, Wartewig T, Ringbloom KG, Martinez-Escala ME, Choi S, et al. Role of B-cells in mycosis Fungoides. Acta Derm Venereol. 2019;20(8):1160–70.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.